RxDoctor Payments Data

Peter di Martino, MD

Interventional Cardiology · Hudson, FLNPI 1548476807

Payments from drug & device makers

$37,572in general payments, 2019–2025

Across 131 payments — averaging $286.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$34K
  • Johnson & Johnson$742
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$560
  • Corcept Therapeutics$445
  • Medtronic$340
  • Shockwave Medical, Inc$319
  • plus $1K from 16 others

What the payments were for

  • Travel & lodging$1760%
  • Food & beverage$3,5519%
  • Education$110%
  • Other$33,83390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,572 in reported general payments places this provider in the 75th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$208,165
Medicare patients
931
Services billed
4,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban123$120,848
EliquisApixaban88$114,098
BrilintaTicagrelor38$23,995
EntrestoSacubitril/Valsartan23$16,308
Dabigatran EtexilateDabigatran Etexilate Mesylate11$4,070
Metoprolol Succinate119$2,075
Diltiazem 24hr Er (Cd)Diltiazem Hcl34$1,363
Atorvastatin Calcium125$1,168
Isosorbide Mononitrate ErIsosorbide Mononitrate99$1,101
Losartan Potassium106$1,050
ClopidogrelClopidogrel Bisulfate96$969
Lisinopril110$887
Metoprolol Tartrate127$728
Nitroglycerin33$667
Carvedilol72$578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$742$120,848123 claims
PfizerEliquis$219$114,09888 claims
AstraZenecaBrilinta$63$23,99538 claims
NovartisEntresto$85$16,30823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Hudson

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →